By Julie Steenhuysen CHICAGO, May 31 (Reuters) - Revolution Medicine's experimental pancreatic cancer pill doubled survival ...

New research shows a novel pill is helping people with advanced pancreatic cancer live longer. It's not a cure, as the drug's ...

The experimental drug daraxonrasib, which doubled survival time in patients with advanced pancreatic cancer, may also prove effective for lung, colon and ovarian cancers.

Daraxonrasib, which nearly doubled patients' survival time, fights the disease in a new way. It bear-hugs a cancer protein that drives cell growth.

Pancreatic cancer is notoriously lethal. But new treatments mean that may be changing, and people with the disease now have more reason to hope than ever before.

The overall survival rate for people who got daraxonrasib was 13.2 months, nearly double the 6.7 months people survived on standard chemotherapy alone.

Former Sen. Ben Sasse of Nebraska reveals an experimental cancer drug helped shrink his tumors by 76% after a stage 4 metastatic pancreatic cancer diagnosis.

A new blood test detected early-stage pancreatic cancer with 87.5% accuracy in a study of 672 people. The test combines four protein biomarkers to better distinguish cancer from noncancerous ...

A new daily pill called daraxonrasib is showing promise against advanced pancreatic cancer in a first-in-human trial of 168 patients with RAS mutations.

An experimental pancreatic cancer pill, daraxonrasib, has shown to double survival rates and improve quality of life compared to chemotherapy. Read more at straitstimes.com. Read more at straitstimes.

The new oral medication, daraxonrasib, has been shown to meaningfully extend the lives of patients with late-stage pancreatic ...